Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Atrial fibrillation (AF) is the most common sustained arrhythmia and various AF disease management strategies can be utilized.
Methods: A prospective, randomized pilot study of two AF disease management strategies was conducted at a single university hospital in patients newly diagnosed with AF. The impact of low molecular weight heparin (LMWH) on AF management strategies is discussed with respect to the current guidelines for AF management, existing data on LMWH for AF, and recent investigations pertaining to AF.
Results: 18 patients were enrolled. The accelerated emergency department based strategy utilizing LMWH resulted in a significant reduction in length of stay (2.1 ± 2.3 versus <1 day) and a trend toward lower costs ($1,706 ± 1,512 versus $879 ± 394; p = 0.15) when compared to the more traditional strategy of hospital admission. Measured clinical outcomes were similar for both treatment strategies.
Conclusions: The investigation showed that an outpatient, emergency department based disease management strategy for new, uncomplicated AF could result in clinically acceptable, cost-effective innovations in AF treatment strategies. LMWH is an example of an agent allowing innovations in disease management strategies.
- Go, AS, Hylek, EM, Phillips, KA, Chang, Y, Henault, LE, Selby, JV, Singer, DE. (2001) Prevalence of undiagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: pp. 2370-2375
- Kim, MH, Morady, F, Conlon, B, Kronick, S, Lowell, M, Bruckman, D, Armstrong, WF, Eagle, KA. (2002) A prospective, randomized, controlled trial of an emergency departmentbased atrial fibrillation treatment strategy with lowmolecular-weight-heparin. Ann Emerg Med 40: pp. 187-192
- JAmColl Cardiol 38: pp. 1-35
- Hirsh, J, Fuster, V, Ansell, J, Halperin, JL. (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107: pp. 1692-1711
- Connolly, SJ. (2003) Preventing stroke in patients with atrial fibrillation: Current treatments and new concepts. Am Heart J 145: pp. 418-423
- Nutescu, E, Racine, E. (2002) Traditional versus modern anticoagulant strategies: Summary of the literature. Am J Health-Syst Pharm 59: pp. S7-14
- Kim, MH, Decena, BF, Bruckman, D, Eagle, KA. (2003) Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation. Am Heart J 145: pp. 665-669
- The Advisory Board Company (Cardiovascular Roundtable). Post-CABG atrial fibrillation: Advanced strategies for prevention and efficient treatment. Washington, D.C., 2000.
- Harenberg, J, Weuster, B, Pfitzer, M, Dempfle, CE, Stehle, G, Kubler, W, Schlierf, G. (1993) Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemostas 19: pp. 116-121
- Harenberg, J, Huhle, G, Piazolo, L, Giese, C, Heene, DL. (1997) Longterm anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular weight heparin. Semin Thromb Hemostas 23: pp. 167-172
- Roijer, A, Eskilsson, J, Olsson, B. (2000) Transesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Eur Heart J 21: pp. 837-847
- Philippon, F, O'Hara, GE (2003) DALTON Study: A randomized study comparing outpatient dalteparin administration to inpatient heparin for the initiation of anticoagulation in atrial fibrillation. JAmColl Cardiol 41: pp. 85A
- Nixdorff, U, Stellbrink, C, Hofmann, T, Hanrath, P, Lehmacher, W, Schmidt-Lucke, A (2003) Comparison of the safety and efficacy of enoxaparin with unfractionated heparin and phenprocoumon as anticoagulation in cardioversion of nonvalvular atrial fibrillation. J AmColl Cardiol 41SupplA: pp. 85A
- Albers, GW, Dalen, JE, Laupacis, A, Manning, WJ, Peterson, P, Singer, DE. (2001) Antithrombotic therapy in atrial fibrillation (Sixth ACCP Consensus Conference on Antithrombotic Therapy). Chest 119: pp. 194S-206S
- Bjerkelund, CJ, Orning, OM. (1969) The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. AmJ Cardiol 23: pp. 208-216
- Arnold, AZ, Mick, MJ, Mazurek, RP, Loop, FD, Trohman, RG. (1992) Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or flutter. J AmColl Cardiol 19: pp. 851-855
- Klein, AL, Grimm, RA, Murray, RD, Apperson-Hansen, C, Asinger, RW, Black, IW, Davidoff, R, Erbel, R, Halperin, JL, Orsinelli, DA, Porter, TR, Stoddard, MF. (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344: pp. 1411-1420
- Murray, RD, Deitcher, SR, Shah, A, Jasper, SE, Bashir, M, Grimm, RA, Klein, AL. (2001) Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided lowmolecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr 14: pp. 200-208
- Murray, RD, Shah, A, Jasper, SE, Goodman, A, Deitcher, SR, Katz, WE, Malouf, JF, Stoddard, MF, Grimm, RA, Klein, AL (2000) Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: The ACUTE II pilot study. Am Heart J 139: pp. e5
- Stellbrink, C, Hanrath, P, Nixdorff, U, Hofmann, T, Lehmacher, W, Kuhle, K, Fetsch, T, Grewe, R, Schmidt-Lucke, JA. (2002) Anticoagulation in cardioversion using enoxaparin study group. Zeitschrift fur Kardiologie 91: pp. 249-254
- A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: pp. 1825-1833
- Lip, GYH, Hart, RG, Conway, DSG. (2002) Antithrombotic therapy for atrial fibrillation. BMJ 325: pp. 1022-1025
- Sherman, DG, Kim, S, Boop, B, Corley, S, DiMarco, J, Hart, RG, Haywood, LJ, Hoyte, K, Kaufman, ES, Kim, M, Nasco, E, Waldo, A (2003) The occurrence and characteristics of stroke events in the AFFIRM study. Neurology 60: pp. A326
- Zimetbaum, PJ, Josephson, ME, McDonald, MJ, McClennen, S, Korley, V, Ho, KK, Papageorgiou, P, Cohen, DJ. (2000) Incidence and predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol 36: pp. 1223-1227
- Koenig, BO, Ross, MA, Jackson, RE. (2002) An emergency department observation unit protocol for acute-onset atrial fibrillation is feasible. Ann Emerg Med 39: pp. 374-381
- Mulcahy, B, Coates, WC, Henneman, PL, Lewis, RJ. (1996) New-onset atrial fibrillation: When is admission medically justified?. Acad Emerg Med 3: pp. 114-119
- Weigner, MJ, Thomas, LR, Patel, U, Schwartz, JG, Burger, A, Douglas, PS, Silverman, DI, Manning, WJ. (2001) Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: Short-term safety and impact on maintenance of sinus rhythm at one year. Am J Med 110: pp. 694-702
- Kim, MH, Krishnan, K, Jain, S, Decena, BF. (2001) Time course and frequency of subtherapeutic anticoagulation for newly prescribed warfarin anticoagulation before elective cardioversion of atrial fibrillation or flutter. Am J Cardiol 88: pp. 1428-1431
- Ginsberg JA, Crowther MA, White RH, Ortel TL. Anticoagulation therapy. Hematology 2001:339–357.
- Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future
Cardiac Electrophysiology Review
Volume 7, Issue 4 , pp 397-400
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- low molecular weight heparin
- atrial fibrillation